IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study
Jing, Zhi-Cheng1; Yu, Zai-Xin2; Shen, Jie-Yan3; Wu, Bing-Xiang4; Xu, Kai-Feng5; Zhu, Xian-Yang6; Pan, Lei7; Zhang, Zhuo-Li8; Liu, Xue-Qin8; Zhang, Yu-Shun9; Jiang, Xin1; Galie, Nazzareno10; Efficacy Safety Vardenafil Treatme
关键词pulmonary hypertension phosphodiesterase inhibitors vardenafil exercise hemodynamics
刊名AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
2011-06-15
DOI10.1164/rccm.201101-0093OC
183期:12页:1723-1729
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Critical Care Medicine ; Respiratory System
资助者Shanghai Pujiang Program ; Actelion ; Bayer Schering ; Pfizer ; United Therapeutics ; GlaxoSmithKline ; Eli Lilly ; Bayer ; Shanghai Pujiang Program ; Actelion ; Bayer Schering ; Pfizer ; United Therapeutics ; GlaxoSmithKline ; Eli Lilly ; Bayer
研究领域[WOS]General & Internal Medicine ; Respiratory System
关键词[WOS]NITRIC-OXIDE ; SILDENAFIL ; INHIBITORS ; THERAPY ; TRIAL ; MULTICENTER ; DISEASE ; CELLS ; PDE5
英文摘要

Rationale: Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy with these agents has not been conclusively shown to reduce clinical worsening events.

Objectives: To evaluate the safety and efficacy of the phosphodiesterase type 5 inhibitor vardenafil in Chinese patients with PAH.

Methods: In a randomized, double-blind, placebo-controlled study, 66 patients with PAH were randomized 2:1 to vardenafil (5 mg once daily for 4wk then 5mg twice daily; n 44) or placebo (n = 22) for 12 weeks. Patients completing this phase were then treated with openlabel vardenafil (5 mg twice daily) for a further 12 weeks.

Measurements and Main Results: At Week 12, the mean placebocorrected 6-minute walking distance was increased with vardenafil (69 m; P<0.001), and this improvement was maintained for at least 24 weeks. Vardenafil also increased the mean placebo-corrected cardiac index (0.39 L.min(-1) . m(-2); P = 0.005) and decreased mean pulmonary arterial pressure and pulmonary vascular resistance (-5.3 mm Hg, P = 0.047; -4.7 Wood U, P = 0.003; respectively) at Week 12. Four patients in the placebo group (20%) and one in the vardenafil group (2.3%) had clinical worsening events (hazard ratio 0.105; 95% confidence interval, 0.012-0.938; P = 0.044). Vardenafil was associated with only mild and transient adverse events.

Conclusions: Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily.

语种英语
所属项目编号08PJ14086
资助者Shanghai Pujiang Program ; Actelion ; Bayer Schering ; Pfizer ; United Therapeutics ; GlaxoSmithKline ; Eli Lilly ; Bayer ; Shanghai Pujiang Program ; Actelion ; Bayer Schering ; Pfizer ; United Therapeutics ; GlaxoSmithKline ; Eli Lilly ; Bayer
WOS记录号WOS:000292305600025
Citation statistics
Cited Times:94[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67067
Collection北京大学第一临床医学院
作者单位1.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Cardiopulm Circulat, Shanghai 200433, Peoples R China
2.Cent S Univ, Xiangya Hosp, Dept Cardiol, Changsha, Hunan, Peoples R China
3.Shanghai Jiao Tong Univ, Renji Hosp, Dept Cardiol, Shanghai 200030, Peoples R China
4.Haerbin Med Univ, Affiliated Hosp 1, Dept Cardiol, Haerbin, Peoples R China
5.Beijing Union Med Coll Hosp, Dept Resp Med, Beijing, Peoples R China
6.Beijing Shijitan Hosp, Dept Pulm Vasc Dis, Beijing, Peoples R China
7.Univ Bologna, Cardiovasc Dept, Bologna, Italy
8.Gen Hosp Shenyang Mil Command, Dept Congenital Heart Dis, Shenyang, Peoples R China
9.Beijing Univ, Hosp 1, Dept Rheumatol & Pediat Cardiol, Beijing 100871, Peoples R China
10.Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiol, Xian 710049, Peoples R China
Recommended Citation
GB/T 7714
Jing, Zhi-Cheng,Yu, Zai-Xin,Shen, Jie-Yan,et al. Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,2011,183(12):1723-1729.
APA Jing, Zhi-Cheng.,Yu, Zai-Xin.,Shen, Jie-Yan.,Wu, Bing-Xiang.,Xu, Kai-Feng.,...&Efficacy Safety Vardenafil Treatme.(2011).Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study.AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,183(12),1723-1729.
MLA Jing, Zhi-Cheng,et al."Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study".AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 183.12(2011):1723-1729.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Jing, Zhi-Cheng]'s Articles
[Yu, Zai-Xin]'s Articles
[Shen, Jie-Yan]'s Articles
百度学术
百度学术Similar articles in
[Jing, Zhi-Cheng]'s Articles
[Yu, Zai-Xin]'s Articles
[Shen, Jie-Yan]'s Articles
必应学术
必应学术Similar articles in
[Jing, Zhi-Cheng]'s Articles
[Yu, Zai-Xin]'s Articles
[Shen, Jie-Yan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.